An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN)

Project: Research project

Project Details

StatusActive
Effective start/end date12/16/25 → 12/15/29

Funding

  • Biogen Idec, Inc ( Award #299PN301): $29,038.00